Business Context and Reporting Period
This Form 8-K was filed by Chicago Mercantile Exchange Holdings Inc. on April 25, 2005. The report details a material definitive agreement entered into by its wholly owned subsidiary, Chicago Mercantile Exchange Inc. ("CME"), with The Nasdaq Stock Market, Inc. ("Nasdaq").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance data.
Material Changes
The primary material change is the amendment to the License Agreement originally effective October 9, 2003, between CME and Nasdaq. Key modifications include:
- Extension of the exclusive license renewal period from October 9, 2011, to October 9, 2012.
- Expansion of the license scope to include the Nasdaq Biotechnology Index for trading futures and options on futures based on that index.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The full text of the Amendment is scheduled to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2005.
Investor Verification Points
- Verify the specific terms and financial implications of the expanded license for the Nasdaq Biotechnology Index in the upcoming Form 10-Q.
- Confirm the strategic rationale for extending the exclusive license renewal period by one year.
- Review the original 2003 License Agreement to understand the baseline terms being amended.